<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680677</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 06718</org_study_id>
    <secondary_id>831340</secondary_id>
    <nct_id>NCT03680677</nct_id>
  </id_info>
  <brief_title>Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies</brief_title>
  <official_title>Prospective Analysis of Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if frailty assessments can be used to
      predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell
      therapy, or allogeneic stem cell transplant.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    due to COVID-19
  </why_stopped>
  <start_date type="Actual">September 21, 2018</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Non-Relapse Mortality (NRM) in Frail, Pre-Frail, and Non-Frail patients</measure>
    <time_frame>1-month</time_frame>
    <description>NRM will be defined as death without evidence of disease progression or relapse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NRM by Intensity of Treatment</measure>
    <time_frame>1-month and 6-month</time_frame>
    <description>NRM of frail and pre-frail patients by intensity of treatment</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Leukemia, Acute</condition>
  <condition>MDS</condition>
  <arm_group>
    <arm_group_label>Cancer Directed Therapy or Best Supportive Care</arm_group_label>
    <description>Cancer-directed therapy with intensive regimens, clinical trial, hypomethylating agent, hypomethylating agent combinations, targeted agents alone, or best supportive care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transplant</arm_group_label>
    <description>Bone marrow or peripheral blood graft (BMT) or CAR T-cell therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow or Peripheral Blood Graft (BMT)</intervention_name>
    <description>Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.</description>
    <arm_group_label>Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cancer-directed Therapy or Best Supportive Care</intervention_name>
    <description>Cancer-directed therapy with intensive regimens (&quot;7+3,&quot; Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care.</description>
    <arm_group_label>Cancer Directed Therapy or Best Supportive Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Frailty Assessment</intervention_name>
    <description>Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.</description>
    <arm_group_label>Cancer Directed Therapy or Best Supportive Care</arm_group_label>
    <arm_group_label>Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Two cohorts of patients will be included in this analysis.

        Arm A will include patients 60 years of age and older with a new diagnosis of either acute
        leukemia or MDS who are being evaluated either in the outpatient or inpatient hematologic
        malignancies department at the University of Pennsylvania.

        Arm B will include patients 60 years of age and older with a diagnosis of any hematologic
        malignancy being treated with cellular therapy including allogeneic blood or marrow
        transplantation or CAR T-cells.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Eligibility Criteria Arm A:

          -  Age 60 years or older.

          -  New diagnosis of Acute Leukemia or MDS, or suspected diagnosis.

          -  Able to consent to the study.

        Eligibility Criteria Arm B:

          -  Age 60 years or older with a hematologic malignancy.

          -  Plan to undergo an allogeneic blood or marrow transplantation or CAR T-cell therapy.

          -  Able to consent to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shannon McCurdy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Frailty</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

